Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Active Biotech AB ( (SE:ACTI) ) has issued an update.
Active Biotech AB held its Annual General Meeting on May 28, 2025, where key resolutions included the decision not to pay dividends for 2024 and to carry forward the company’s accumulated loss. The board members and CEO were discharged from liability for 2024, and the existing board members were re-elected, with Michael Shalmi continuing as Chairman. The meeting also authorized the board to issue new shares and/or convertibles up to 30% of the total shares until the next AGM, potentially impacting the company’s financial strategy and shareholder value.
More about Active Biotech AB
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. The company has three main projects: tasquinimod for myelofibrosis, laquinimod for non-infectious uveitis, and naptumomab, an anti-cancer immunotherapy partnered with NeoTX Therapeutics.
Average Trading Volume: 24,204,981
Current Market Cap: SEK329.7M
For an in-depth examination of ACTI stock, go to TipRanks’ Stock Analysis page.